drugset
drugset / Trial / NCT00154739

Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)

NCT00154739 ↗

Phase 2 Completed 86 enrolled National Taiwan University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy of gemcitabine/cisplatin versus gemcitabine/epirubicin in Stage IIIB/IV NSCLC in terms of response rate and overall survival.

Timeline

Start
1998-10
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified — —
Subject Epirubicin Small molecule — —
Background Gemcitabine Small molecule — —

Indications

non-small cell lung carcinoma